pro re nata $221.40 (typically (75%) 23 $250.90 injections (85%) during months Item 612) number 42740 $295.15 $221.40 (75%) $250.90 (85%) Aflibercept drug Ophthalmologist, Consulting Patients acquisition PBS rooms with baseline CRT ≥250 µm Resources provided in association with proposed intervention OCT monitoring Ophthalmologist Consulting Patients Monthly for $250 rooms with the first 6 baseline months, CRT ≥250 then as µm needed Resources provided to deliver standard medical management Ranibizumab Ophthalmologist Consulting TBD TBD alone, drug room acquisition Ranibizumab Ophthalmologist, Consulting TBD TBD Item alone, drug MBS rooms number administration 42738 $295.15 $221.40 (75%) $250.90 (85%) Item number 42739 $295.15 $221.40 (75%) $250.90 (85%)
pro re nata (typically 23 injections during months 612) $221.40 (75%) $250.90 (85%) Item number 42740 $295.15 $221.40 (75%) $250.90 (85%) Aflibercept drug acquisition Ophthalmologist, PBS Consulting rooms Patients with baseline CRT ≥250 µm Resources provided in association with proposed intervention OCT monitoring Ophthalmologist Consulting rooms Patients with baseline CRT ≥250 µm Monthly for the first 6 months, then as needed $250 Resources provided to deliver standard medical management Ranibizumab alone, drug acquisition Ophthalmologist Consulting room TBD TBD Ranibizumab alone, drug administration Ophthalmologist, MBS Consulting rooms TBD TBD Item number 42738 $295.15 $221.40 (75%) $250.90 (85%) Item number 42739 $295.15 $221.40 (75%) $250.90 (85%)